Bioglan AB development vectors are based on four strategic pillars, which should ensure the growth and profitability of the company in the long term and create value for all its stakeholders:
R&D
Development of:
New indications and/or dosage forms of known active principles
Generics with special focus on beta lactam and freeze dried injectable antibiotics
Topical dermatological products
OTCs
Extension of Forte Pharma’s range of food supplements
Identification of collaborative projects with start-ups and biotech research centers
Own brands
Strengthening of own brands oriented to the medical, pharmaceutical and hospital channel.
Search for strategic opportunities to acquire international brands.
Specialized production services
Specialized manufacture for third parties in the four plants that the company owns in Spain and Sweden, with outstanding approach in penicillanic antibiotics in all dosage forms, cephalosporanic antibiotics in vials, topical dermatologicals, and especially, freeze dried vials including biotech.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.